Shots:

• The approval is based on ongoing P1093 (NCT03016533) and ODYSSEY (PENTA20- NCT02259127) studies in pediatric patients aged 4 weeks to 18 years- while the second study involves 2L pediatric patients aged four weeks to 18 years
• The P1093 study was conducted by IMPAACT network in the USA- Brazil- Thailand- South Africa- Zimbabwe- Kenya and Tanzania and ODYSSEY by the PENTA network in Europe- South America- Thailand- Uganda- Zimbabwe- and South Africa
• Tivicay and Tivicay PD are a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used in combination with antiretroviral agents to treat HIV-1 infection in adults and in pediatric patients aged at least 4 weeks and weighing at least 3 kg

Ref: ViiV Healthcare | Image: Behance